SOURCE: StockCall


December 30, 2010 08:31 ET

Opinions on Elan Corp. plc and Alkermes Inc. -- Drug Delivery Sector Facing FDA Crackdowns and Resistance

JOHANNESBURG, SOUTH AFRICA--(Marketwire - December 30, 2010) - offers investors comprehensive research on the drug delivery industry and has completed analytical research on Elan Corp. plc (NYSE: ELN) and Alkermes Inc. (NASDAQ: ALKS). Register with us today at to have free access to these researches. 

The FDA has recently been cracking down on off-label marketing practices in the Drug Delivery sector. Companies are not allowed to promote a drug for a use other than what the FDA initially approved. Doctors are allowed to go beyond this original intention and prescribe drugs however they see fit, but the federal False Claims Act prohibits companies from attempting to originate improper billings to federal health care institutions. Marketing drugs for off-label uses falls under this umbrella and Elan Corp. plc within the sector recently had to pay over $200 million in criminal and civil charges. Investors looking for free research on Elan Corp. plc are welcome to sign up at is an online platform where investors doing their due-diligence on the drug delivery industry can have easy and free access to our analyst research and opinions on Elan Corp. plc and Alkermes Inc.; all investors need to do is register for a complimentary membership at

One reason companies may be looking to stretch the use of pre-existing drugs is because a huge patent cliff is coming during the next few years. To combat this, many companies are looking to mergers and acquisitions to supplement their pipelines and ensure they will have products to offer. Companies are also working to expand into emerging markets where growth is happening at a much higher rate than in the developed world. Register now at to have free access to our reports on the drug delivery industry.

Another area companies within the Drug Delivery sector are focusing is developing new drug delivery systems. Increasing research is being done on gels, nanotechnology, and biologic processes for getting chemicals to specific places within the body. While the FDA has been providing some resistance to new methods, breakthroughs could potentially be enormous opportunities for the sector. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

For the third quarter 2010 financial results for Elan Corp. plc came in with a loss of $43.6 million, whilst Alkermes Inc. posted a narrower loss of $7.7 million on a revenue growth. Investors looking for free research on Alkermes Inc. are welcome to sign up at

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information